Product/Composition:- | Cyclosporine Capsules |
---|---|
Strength:- | 25 mg, 50 mg, 100 mg |
Form:- | Capsules |
Reference Brands:- | Neoral, Sandimmune, Restasis, Celexet(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Cyclosporine capsules inhibit calcineurin, reducing T-cell activation and cytokine production. This immunosuppressant prevents organ rejection in transplant patients and treats autoimmune conditions. Benefits include improved graft survival, decreased immune response, and effective disease control, supporting long-term transplant success and autoimmune disease management.
Cyclosporine capsules, marketed as Neoral and Sandimmune, are approved in the US by the FDA and in the EU via EMA for preventing transplant rejection and autoimmune disorders. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical and quality data, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring regulatory compliance is essential for the safe, effective, and timely approval of cyclosporine capsules worldwide, supporting optimal transplant and autoimmune patient care.